Oncology drug development is costly and risky. Just one drug can take almost a decade with a $1 billion price tag. Yet approval rates can drop as low as 5%. If you wait until registration to think about what stakeholders expect, you may be starting over. Problem is, each of your stakeholders define value differently. Quintiles helps you understand their expectations so you can integrate commercial insights into the development process from the very beginning, identifying the most critical value endpoints to design more efficient clinical trials.